Today: 1 May 2026
GOOG stock rises after hours as Alphabet sets Feb. 4 earnings date; Wiz deal deadline in focus
8 January 2026
1 min read

GOOG stock rises after hours as Alphabet sets Feb. 4 earnings date; Wiz deal deadline in focus

NEW YORK, Jan 8, 2026, 16:34 EST — After-hours

  • Alphabet’s non-voting Class C shares rose about 1% after the close, trading around $326
  • Company set Feb. 4 for fourth-quarter and full-year 2025 results and a conference call
  • EU antitrust clock on Alphabet’s $32 billion Wiz deal now runs to Feb. 10

Alphabet’s non-voting Class C shares (GOOG) rose 1.1% in after-hours trade on Thursday to $326.01, following a choppy session that had the stock swinging between $322.23 and $329.88.

The move comes as investors hunt for the next obvious catalyst for a stock caught between two big questions: how fast Google can keep its ad machine growing, and how much it will need to spend to stay in the AI race. The next few weeks may get choppy, with regulators and earnings both on the calendar.

Spending is the other side of it. CFO Anat Ashkenazi told investors on the company’s last earnings call that Alphabet expected “a significant increase” in capital expenditures in 2026. Depending on how big that jump looks, it could end up shifting how the stock gets valued. Alphabet Investor Relations

Alphabet said it will review its fourth-quarter and full-year 2025 results on Feb. 4, with the earnings release due out ahead of its 4:30 p.m. Eastern conference call.

On the Street, Cantor Fitzgerald upgraded Alphabet to “overweight” and raised its price target to $370, arguing the company is positioned to benefit across the AI stack. Analyst Deepak Mathivanan called Alphabet the “king of all AI trades” in a note. (“Overweight” is a broker rating that signals an expectation of outperformance versus peers or a benchmark.) MarketWatch

Regulators aren’t out of the picture. EU antitrust officials said they will decide by Feb. 10 whether to clear Alphabet’s $32 billion bid for cybersecurity firm Wiz, or open a deeper probe — a process that can drag on for months and sometimes ends in concessions. If it goes through, it would be Alphabet’s biggest deal and would sharpen its cloud security pitch against Amazon and Microsoft.

In a separate Europe thread, Big Tech looks likely to sidestep the EU’s planned Digital Networks Act, avoiding hard new obligations, as large U.S. platforms are instead funneled into a voluntary setup, sources told Reuters.

But after the stock’s sharp run-up, it’s become jumpy at any hint that AI features are pinching ad pricing, or that expenses are rising faster than revenue. A tougher-than-expected stance from regulators on Wiz would add another pressure point.

Next up is Feb. 4, when Alphabet reports. Investors will be watching for ad trends, cloud demand and how big the 2026 spending step-up looks. Then the EU’s Wiz decision deadline comes due on Feb. 10.

Stock Market Today

  • Avalyn Pharma upsizes IPO to $300 million, Alector halts study with GSK
    May 1, 2026, 12:10 AM EDT. Avalyn Pharma, a Boston-based biotech, is raising $300 million by selling 16.5 million shares at $18 each in an upsized initial public offering (IPO). The capital raise aims to fund its drug development programs. Separately, Alector, in partnership with GlaxoSmithKline (GSK), has terminated another clinical study, though further details remain limited. These moves reflect ongoing volatility and strategic shifts within the biotech sector as firms adjust pipelines and capital strategies amid challenging market conditions.

Latest article

Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz

US Stock Market Today: Live Updates 01.05.2026

1 May 2026
LIVEMarkets rolling coverageStarted: May 1, 2026, 12:00 AM EDTUpdated: May 1, 2026, 12:14 AM EDT Avalyn Pharma upsizes IPO to $300 million, Alector halts study with GSK May 1, 2026, 12:10 AM EDT. Avalyn Pharma, a Boston-based biotech, is raising $300 million by selling 16.5 million shares at $18 each in an upsized initial public offering (IPO). The capital raise aims to fund its drug development programs. Separately, Alector, in partnership with GlaxoSmithKline (GSK), has terminated another clinical study, though further details remain limited. These moves reflect ongoing volatility and strategic shifts within the biotech sector as firms adjust pipelines
Sandisk Stock Falls After Blowout Q3 Earnings as AI Storage Rally Hits a High Bar

Sandisk Stock Falls After Blowout Q3 Earnings as AI Storage Rally Hits a High Bar

1 May 2026
Sandisk shares dropped about 6% in after-hours trading Thursday despite reporting fiscal Q3 revenue of $5.95 billion, up 251% from a year earlier, and net income of $3.62 billion. The company announced a $6 billion buyback and forecast Q4 revenue of up to $8.25 billion. Gross margin rose to 78.4%. Shares had closed at $1,096.51 before slipping to about $1,030.
Apple Stock Slips After Earnings Beat as iPhone Supply Snag Clouds $100 Billion Buyback

Apple Stock Slips After Earnings Beat as iPhone Supply Snag Clouds $100 Billion Buyback

1 May 2026
Apple reported fiscal Q2 revenue of $111.2 billion and earnings of $2.01 per share, beating analyst estimates. The board approved a $100 billion share buyback and raised the dividend. Shares fell about 1% after hours as iPhone sales missed forecasts and chip supply remained tight. Investors are watching for clarity on AI strategy and the upcoming CEO transition to John Ternus.
Meta stock dips as China opens Manus AI deal review — what investors watch next
Previous Story

Meta stock dips as China opens Manus AI deal review — what investors watch next

XRP price slips as spot ETF outflows break streak; U.S. jobs report in focus
Next Story

XRP price slips as spot ETF outflows break streak; U.S. jobs report in focus

Go toTop